Questions and answers in chronic urticaria: where do we stand and where do we go?

This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. In 2011, a report of the GA2LEN task force on urticaria outlined important and unanswered questions in chronic urticaria (CU). These included, but were not limi...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 30; no. S5; pp. 7 - 15
Main Authors Maurer, M., Church, M. K., Marsland, A. M., Sussman, G., Siebenhaar, F., Vestergaard, C., Broom, B.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.07.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. In 2011, a report of the GA2LEN task force on urticaria outlined important and unanswered questions in chronic urticaria (CU). These included, but were not limited to, questions on the epidemiology and course of chronic spontaneous urticaria (CSU) [also called chronic idiopathic urticaria (CIU)], the resources allocated for the diagnosis and treatment of CSU, whether patients with angioedema as an isolated symptom can be regarded as a subgroup of CSU, and the efficacy and long‐term safety of therapies. Many of these questions have been addressed by recent studies. Some of the answers obtained raise new questions. Here, we summarize some of the key insights on CU obtained over recent years, and we discuss old and new unmet needs and how to address them with future studies. We need to analyze the influence of recent advances in understanding of the burden of CU on patients and society, disease management and the CU patient journey. Our increased understanding of urticarial pathophysiology and consideration of the patient as a whole will need to be translated to better treatment algorithms and protocols. Actions to address these challenges include the 5th International Consensus Meeting on Urticaria, which will take place later this year. The formation of a global network of Urticaria Centers of Reference and Excellence over the next few years has also been proposed, with the aim of providing consistent excellence in urticaria management and a clear referral route, furthering knowledge of urticaria through additional research and educating/promoting awareness of urticaria.
Bibliography: 
ArticleID:JDV13695
Novartis Pharma AG
ark:/67375/WNG-KZT3Q8TC-9
istex:307547D6ED48C624B9DF88113FC7C0DD4377F53B
Marcus Maurer is, or was recently, a speaker and/or advisor for FAES, Almirall Hermal, Genentech, GSK, Merckle Recordati, Novartis, Sanofi‐Aventis, MSD, Moxie, Takeda, Shire, UCB and Uriach.
Brian Broom has received lecture fees and conference travel assistance from Novartis related to Global Urticaria Forum, Berlin 2015.
Gordon Sussman has recently acted as a consultant and speaker for Novartis, Merck, CSL Behring, Pfizer and Shire.
In the online version of this article, additional information is available by clicking on the icons in the margins
Christian Vestergaard has acted as a speaker for Novartis, Abbvie, LEO Pharma, and served on advisory boards for Novartis, Abbvie and Sanofi.
Key to symbols
This supplement was funded by Novartis Pharma AG. It is a publication of the Novartis supported medical education meeting that took place in Berlin in November 2015. The publication presents views of the authors and not Novartis.
Alexander Marsland has acted as a speaker and/or advisor for Galderma, GSK, Novartis and UCB Pharma.
Funding source
Conflicts of interest
Frank Siebenhaar is, or was recently, a speaker or advisor for Abbott, Braun, Dr. Pfleger, Moxie, Novartis, Patara Pharma, Procter & Gamble and Uriach.
[] Slide; [] Video; [] Infographic
Martin Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, Moxie, MSD, Novartis, UCB Pharma, Sanofi‐Aventis and Uriach.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.13695